Literature DB >> 11466624

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

K Sibley1, P Stern, M A Knowles.   

Abstract

Mutations in FGFR3 have been identified in several tumour types including bladder carcinoma, cervical carcinoma, and multiple myeloma. In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date. We have now investigated the frequency of FGFR3 mutation in a panel of 125 tumours and 13 cell lines from various other organs. We analysed the mutation hotspots in exons 7, 10 and 15 by direct DNA sequencing, and found one mutation in exon 7 (S249C) in 1/28 (3.5%) cervical tumours. Mutations were not detected in stomach, rectum, colon, prostate, ovarian, breast, brain, or renal tumours, nor were they found in any of the cell lines included in this study. We conclude that FGFR3 is commonly mutated in bladder carcinoma and only rarely in cervical carcinoma. Several tumour types appear not to possess any mutations in FGFR3, suggesting that these mutations are important only in the development of certain types of tumour.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11466624     DOI: 10.1038/sj.onc.1204543

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling.

Authors:  Jian Ren; Deepak Raina; Wen Chen; Guilan Li; Lei Huang; Donald Kufe
Journal:  Mol Cancer Res       Date:  2006-11       Impact factor: 5.852

Review 2.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 3.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer.

Authors:  David J McConkey; Woonyoung Choi; Lauren Marquis; Frances Martin; Michael B Williams; Jay Shah; Robert Svatek; Aditi Das; Liana Adam; Ashish Kamat; Arlene Siefker-Radtke; Colin Dinney
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

4.  Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Authors:  April N Meyer; Christopher W McAndrew; Daniel J Donoghue
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

5.  Trends in stage-specific incidence rates for urothelial carcinoma of the bladder in the United States: 1988 to 2006.

Authors:  Matthew E Nielsen; Angela B Smith; Anne-Marie Meyer; Tzy-Mey Kuo; Seth Tyree; William Y Kim; Matthew I Milowsky; Raj S Pruthi; Robert C Millikan
Journal:  Cancer       Date:  2013-10-10       Impact factor: 6.860

6.  Mutational activation of FGFR3: no involvement in the development of renal cell carcinoma.

Authors:  C G Stoehr; R Stoehr; A Hartmann; F Hofstaedter; K Junker; H Blaszyk; W F Wieland; W Otto; S Denzinger; B Walter
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-28       Impact factor: 4.553

7.  Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.

Authors:  Tao Wang; Zhengsheng Liu; Xuegang Wang; Peide Bai; Anran Sun; Zhiqiang Shao; Rongtuan Luo; Zhun Wu; Kaiyan Zhang; Wei Li; Wen Xiao; Bo Duan; Yongfeng Wang; Bin Chen; Jinchun Xing
Journal:  Cancer Biol Ther       Date:  2020-05-23       Impact factor: 4.742

Review 8.  Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression.

Authors:  David J McConkey; Sangkyou Lee; Woonyoung Choi; Mai Tran; Tadeusz Majewski; Sooyong Lee; Arlene Siefker-Radtke; Colin Dinney; Bogdan Czerniak
Journal:  Urol Oncol       Date:  2010 Jul-Aug       Impact factor: 3.498

9.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

Review 10.  Biology of urothelial tumorigenesis: insights from genetically engineered mice.

Authors:  Xue-Ru Wu
Journal:  Cancer Metastasis Rev       Date:  2009-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.